title: Enhanced humoral immune response correlates with improved disease-free and overall survival in American Joint Committee on Cancer stage II melanoma patients receiving adjuvant polyvalent vaccine.
abstract: OBJECTIVE
  Although the improved overall survival (OS) of patients who receive Canvaxin (CancerVax Corp, Carlsbad, CA) polyvalent vaccine (PV) immunotherapy for metastatic melanoma has been correlated with cellular and humoral immune responses, the mechanisms of vaccine immunotherapy for early-stage melanoma are unclear. Specific immune responses to tumor-associated antigens might correlate with disease-free survival (DFS) and OS in patients receiving adjuvant PV therapy for primary melanoma.
  
  
  METHODS
  Eighty-three patients received PV plus bacille Calmette-Guérin after wide excision of American Joint Committee on Cancer stage II melanoma. Humoral and cellular responses during the first 12 weeks of adjuvant immunotherapy were assessed by serum antibody titers to a tumor-associated 90-kd glycoprotein antigen (TA90) expressed by PV, and by delayed-type hypersensitivity (DTH) skin testing with PV (PV-DTH).
  
  
  RESULTS
  At a median follow-up period of 46.6 months (range, 10.7 to 93.6 months), an increased PV-DTH response seemed to be associated with improved 5-year DFS (54% v 20%) and 5-year OS (75% v 60%), but the correlations were not statistically significant. Anti-TA90 immunoglobulin (Ig) M levels > or = 1:800 were significantly correlated with improved 5-year DFS and improved 5-year OS, and multivariate analysis identified anti-TA90 IgM as an independent prognostic factor for OS and DFS.
  
  
  CONCLUSIONS
  These findings suggest that an increased IgM response in patients receiving PV therapy for stage II melanoma is associated with decreased recurrence and improved survival.
authors.affiliation: Sonya Valley Ghidossi Vaccine Laboratory, Roy E. Coats Research Laboratories, John Wayne Cancer Institute at Saint John's Health Center, 2200 Santa Monica Boulevard, Santa Monica, CA 90404, USA.
authors.forename: L Andrew
authors.initials: LA
authors.lastname: DiFronzo
authors.forename: Rishab K
authors.initials: RK
authors.lastname: Gupta
authors.forename: Richard
authors.initials: R
authors.lastname: Essner
authors.forename: Leland J
authors.initials: LJ
authors.lastname: Foshag
authors.forename: Steven J
authors.initials: SJ
authors.lastname: O'Day
authors.forename: Leslie A
authors.initials: LA
authors.lastname: Wanek
authors.forename: Stacey L
authors.initials: SL
authors.lastname: Stern
authors.forename: Donald L
authors.initials: DL
authors.lastname: Morton
mesh_terms: D000917:Antibody Formation / Q000187:drug effects / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology; D001500:BCG Vaccine / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use*; D018572:Disease-Free Survival; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007074:Immunoglobulin G / Q000096:biosynthesis; D007075:Immunoglobulin M / Q000096:biosynthesis; D008297:Male; D008545:Melanoma / Q000276:immunology* / Q000628:therapy*; D016016:Proportional Hazards Models; D016019:Survival Analysis
chemical_list: D000951:Antigens, Neoplasm; D001500:BCG Vaccine; D019496:Cancer Vaccines; C464842:Canvaxin; D007074:Immunoglobulin G; D007075:Immunoglobulin M